Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
摘要:
A Hit-to-Lead optimisation programme was carried out on a high throughput screening hit, the thiazolopyrimidine 1, resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist 29. (c) 2005 Elsevier Ltd. All rights reserved.
Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
摘要:
A Hit-to-Lead optimisation programme was carried out on a high throughput screening hit, the thiazolopyrimidine 1, resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist 29. (c) 2005 Elsevier Ltd. All rights reserved.
The invention provides certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
[EN] NOVEL THIAZOLOPYRIMIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES DE THIAZOLOPYRIMIDINE
申请人:ASTRA PHARMA PROD
公开号:WO2000009511A1
公开(公告)日:2000-02-24
The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.